NVCN - Neovasc Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.8800
+0.0200 (+0.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close2.8600
Open2.9100
Bid2.8300 x 800
Ask2.8900 x 1200
Day's range2.7700 - 2.9100
52-week range1.2400 - 8.6500
Volume131,229
Avg. volume211,232
Market cap31.946M
Beta (5Y monthly)3.03
PE ratio (TTM)N/A
EPS (TTM)-3.7180
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.88
  • GlobeNewswire

    Neovasc Has Filed for CE Mark for Tiara TA Transapical Mitral Valve Replacement System

    Mitral Valve disease is one of the most common forms of heart disease that affects millions of patients worldwide. The Tiara TA transapical mitral valve replacement system uses a percutaneous or “key-hole” incision in the chest to completely replace the native mitral valve and avoids the need for heart-lung bypass.

  • GlobeNewswire

    Neovasc Provides Corporate Update

    After a marked slowdown that began in March, Reducer implant rates in Germany, where the company has a direct sales team and NUB Status 1 designation for reimbursement, are once again approaching pre-COVID-19 levels. As previously discussed, the company is aware of the backlog of potential Reducer patients related to COVID-19 and the reduction in elective procedures in select European markets and we look forward to continued acceleration. The National Institute for Health and Care Excellence (NICE) Interventional Procedures Programme in the U.K. has invited Neovasc to participate in guidance development for Reducer treatment of refractory angina.

  • GlobeNewswire

    Neovasc Announces Offering of Convertible Debt and Warrants for Gross Proceeds of up to US$5.0 Million, Warrant Exchange Transaction and Repayment of 2017 Convertible Notes and Related Settlement

    The combined transactions improve the fully diluted share capital of the Company, and are designed to allow the Company to pursue refinancing options with long term investors who understand the overall potential of the Company’s portfolio of products. Following the completion of the transactions the Company will have an issued and outstanding share capital of 12,306,270 common shares of the Company (“Common Shares”) and a fully diluted share capital of 21,226,518.

  • GlobeNewswire

    Neovasc Announces First Quarter Financial Results

    Promotes John Panton to Chief Quality Officer VANCOUVER and MINNEAPOLIS, MN, May 07, 2020 -- via NEWMEDIAWIRE – Neovasc Inc. ("Neovasc" or the "Company").

  • GlobeNewswire

    Neovasc Announces Receipt of Nasdaq Extension to Satisfy Market Cap Rule

    To evidence compliance with the MVLS requirement, the Company must evidence an MVLS of at least $35 million based upon the consolidated closing bid price of Neovasc’s common stock for a minimum of 10 consecutive business days. The Company intends to pursue opportunities to raise additional capital with the goal to timely evidence compliance with the MVLS requirement.

  • Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Neovasc to Report First Quarter Financial Results on May 7, 2020

    VANCOUVER and MINNEAPOLIS, MN, April 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended March 31, 2020 after the market close on May 7, 2020. Neovasc Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the company’s results at 4:30 PM Eastern Time. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.

  • GlobeNewswire

    Neovasc Announces Fourth Quarter and Full Year 2019 Financial Results

    VANCOUVER and MINNEAPOLIS, March 30, 2020 -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally.

  • GlobeNewswire

    Neovasc to Report Fourth Quarter and Full Year 2019 Financial Results on March 30, 2020

    VANCOUVER, March 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and year ended December 31, 2019 after the market close on March 30, 2020. Neovasc CEO Fred Colen and CFO Chris Clark will host a conference call to review the company’s results at 4:30 PM Eastern Time. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.

  • Neovasc (NVCN) Releases Update on Reducer and Tiara Products
    Zacks

    Neovasc (NVCN) Releases Update on Reducer and Tiara Products

    Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.

  • GlobeNewswire

    Neovasc Updates Investors at SVB Leerink 9th Annual Global Healthcare Conference

    The Company is increasingly bullish on Reducer and remains focused on capitalizing on the improving market dynamics for the device. Management believes the landscape for the treatment of refractory angina and ischemia is changing favorably. The increasing rate of diagnosis of microvascular disease provides support for the treatment of refractory angina with the Reducer in appropriate patients.

  • GlobeNewswire

    Neovasc Reducer Featured in Peer Reviewed EuroIntervention and PCR Online

    In the study published in EuroIntervention, “Coronary sinus Reducer implantation results in improved oxygen kinetics at cardiopulmonary exercise test in patients with refractory angina,” in patients with obstructive coronary artery disease suffering from chronic refractory angina, treatment with coronary sinus Reducer implantation was associated with objective improvement in exercise capacity and oxygen kinetics tested by cardiopulmonary exercise testing as well as improvement in angina symptoms and quality of life. Patients with chronic refractory angina were treated with Reducer implantation at 2 medical centers: the Antwerp Cardiovascular Center in Belgium and the Tel Aviv Medical Center in Israel.

  • GlobeNewswire

    Neovasc Will Request Nasdaq Hearing After Company Received Expected Delisting Determination From Nasdaq Staff

    On February 19, 2020, the Company received the expected notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff had determined to delist the Company’s common shares from Nasdaq unless the Company requests a hearing before the Panel by February 26, 2020, which the Company will do. This request will ordinarily stay any further action by the Staff and the Company’s securities are expected to continue to be eligible to trade on Nasdaq at least pending the ultimate conclusion of the hearing process.

  • GlobeNewswire

    Neovasc to Participate in SVB Leerink 9th Annual Global Healthcare Conference on February 26, 2020

    A replay of the webcast will be accessible through the Neovasc investor relations website approximately one hour following the completion of the event. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.

  • GlobeNewswire

    Neovasc Achieves Design Freeze for Transfemoral Trans-septal Tiara™ Mitral Valve System

    VANCOUVER and MINNEAPOLIS, Feb. 12, 2020 -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally.

  • GlobeNewswire

    Neovasc Initiates Independent Inquiry Into Trading of its Shares

    Professor Mitts will examine trading history related to the unusual volume and downward pressure on the price of the common shares of the Company after positive news releases, and the unusual volume and downward pressure on the price of the common shares of the Company after the Company announced an update on its compliance with the Nasdaq’s minimum value of listed securities rule. The findings of the commissioned report may be provided to appropriate authorities, including the Nasdaq.

  • GlobeNewswire

    Neovasc Provides Update on Nasdaq Compliance

    The MVLS test is based on the closing bid price each day. If the Company maintains an MVLS of at least $35 million for ten consecutive trading days, it will satisfy the MVLS requirement before the Nasdaq grace period ends on February 17, 2020. The Nasdaq has discretion to require satisfaction of the $35 million MVLS requirement for a period in excess of ten consecutive trading days.

  • GlobeNewswire

    Neovasc Announces Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina

    VANCOUVER, Jan. 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Institut für das Entgeltsystem im Krankenhaus ("InEK"), (the German Institute for the Hospital Remuneration System), has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation once again for 2020. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedures that can be utilized by the hospital before reaching full reimbursement eligibility.

  • GlobeNewswire

    Neovasc Announces Executive Steering Committee for Transfemoral Trans-septal Tiara Program

    The Company intends to enroll the first patient in a feasibility trial in late 2020, pending achievement of development and regulatory milestones. “We believe we have assembled a world-class executive steering committee for the TF/TS Tiara program”, said Fred Colen, President and CEO of Neovasc.

  • GlobeNewswire

    Neovasc Advances New Transfemoral Trans-septal Tiara Design Concept After Further Successful Tests

    VANCOUVER, Jan. 24, 2020 -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter.

  • GlobeNewswire

    Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations in Germany

    At a workshop held January 22, 2020 in Landshut by the Krankenhaus Achdorf, in cooperation with Berlin-Chemie and Neovasc, Dr. Stylianos Pyxaras presented the Reducer as a new treatment option for chronic angina. “We are encouraged by the growing use and satisfaction of physicians with the outcomes of the Reducer Therapy for their patients,” said Fred Colen, President and Chief Executive Officer of Neovasc.

  • GlobeNewswire

    Updates on Reducer and Tiara Programs Will be Presented at Advanced Cardiovascular Intervention 2020 Meeting

    Neovasc Provides Corporate Update Vancouver, BC, Jan. 21, 2020 -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the.

  • GlobeNewswire

    Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™

    VANCOUVER, Jan. 15, 2020 -- via NEWMEDIAWIRE – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter.

  • GlobeNewswire

    Neovasc Inc. Investor Update

    “We closed 2019 by doing what we said we would do, when we said we would do it,” said Fred Colen, President and CEO of Neovasc. Thus far approximately 1,300 patients have received the device and results have been encouraging, demonstrating effectiveness in treating refractory angina with a strong safety profile.

  • GlobeNewswire

    Neovasc Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market

    Vancouver, Canada, Jan. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules of an aggregate of 1,185,000 series A units ("Series A Units") and 1,241,490 series B units ("Series B Units" and together with the Series A Units, the "Units") at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit for aggregate gross proceeds to the Company of approximately US$10 million, before deducting placement agent’s fees and estimated expenses of the Offering payable by the Company. Each Series A Unit consists of one common share of the Company and one warrant (a "Warrant") to purchase one common share.